Evidence map›Paper›PMID 36839474›Full record

ArticlePathogens (Basel, Switzerland)2023

Hepatitis C Virus Micro-Elimination Plan in Southern Italy: The "HCV ICEberg" Project.

Carmine Coppola, Loreta A Kondili, Laura Staiano, Simona Cammarota, Anna Citarella, Mirko Pio Aloisio, Angelo Annunziata, Francesca Futura Bernardi, Aldo D'Avino, Michele D'Orazio and 6 more

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Carmine CoppolaDepartment of Internal Medicine, Unit of Hepatology and Interventional Ultrasonography, OORR Area Stabiese, 80054 Gragnano, Italy.
Loreta A KondiliCenter for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0003-2656-224X
Laura StaianoDepartment of Internal Medicine, Unit of Hepatology and Interventional Ultrasonography, OORR Area Stabiese, 80054 Gragnano, Italy.
Simona CammarotaLinkHealth Health Economics, Outcomes & Epidemiology S.R.L., 80143 Naples, Italy.
Anna CitarellaLinkHealth Health Economics, Outcomes & Epidemiology S.R.L., 80143 Naples, Italy.
Mirko Pio AloisioLocal Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.ORCID 0000-0002-3903-8028
Angelo AnnunziataLocal Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.
Francesca Futura BernardiGeneral Direction of Health Care & Regional Health System Coordination, Drug & Device Politics, Campania Region, 80143 Naples, Italy.
Aldo D'AvinoLocal Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.
Michele D'OrazioLocal Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.
Marianna FogliaseccaLinkHealth Health Economics, Outcomes & Epidemiology S.R.L., 80143 Naples, Italy.
Mario FuscoCancer Registry, Local Health Unit Naples 3 South, 80100 Naples, Italy.
Federica PisanoDepartment of Internal Medicine, Unit of Hepatology and Interventional Ultrasonography, OORR Area Stabiese, 80054 Gragnano, Italy.
Adriano VercellonePharmacy Unit, Local Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.
Elvira BiancoHealthcare Direction, Local Health Unit Naples 3 South, 80059 Castellammare di Stabia, Italy.
Ugo TramaGeneral Direction of Health Care & Regional Health System Coordination, Drug & Device Politics, Campania Region, 80143 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the feasibility of a local action program for HCV micro-elimination in highly endemic areas. Retrospective analysis: administrative and laboratory data (Local Health Unit, southern Italy) were integrated to quantize the anti-HCV-positive subjects not RNA tested and untreated HCV-infected subjects (2018-2022). Prospective analysis: all subjects admitted to a division of the LHU largest hospital (2021-2022) were tested for HCV, with linkage of active-infected patients to care. Overall, 49287 subjects were HCV-Ab tested: 1071 (2.2%) resulted positive without information for an HCV RNA test and 230 (0.5%) had an active infection not yet cured. Among 856 admitted subjects, 54 (6.3%) were HCV-Ab+ and 27 (3.0%) HCV RNA+. Of HCV-infected patients, 22.2% had advanced liver disease, highlighting the need for earlier diagnosis; 27.7% were unaware of HCV infection; and 20.4% were previously aware but never referred to a clinical center. Of these, 26% died and 74% received treatment. Our study emphasizes the value of an active HCV hospital case-finding program to enhance diagnosis in patients with several comorbidities and to easily link them to care. Our data strongly suggest extending this program to all hospital wards/access as a standard of care, particularly in highly endemic areas, to help HCV disease control and take steps in achieving the elimination goals.

Indexed as

administrative datacascade of careHCV micro-eliminationlinkage to careopportunistic screening

Identifiers

PMID36839474
PMCPMC9967587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.